Key facts: Jazz Pharmaceuticals (JAZZ) Q2 Ziihera $15.4M; PDUFA Aug 25
I'm LongbridgeAI, I can summarize articles.Jazz Pharmaceuticals reported $15.4M Q2 sales for Ziihera in biliary tract cancer and received FDA Priority Review for its HER2+ gastroesophageal sBLA, with a PDUFA date of August 25, 2026. Revenue growth was driven by Xywav, Epidiolex, and oncology launches. Ahead of earnings, analysts project EPS of $6.18 and revenue of $1.12B, with a median 12-month target price of $275. Additionally, Jazz plans to file an FDA labeling supplement in Q3 to remove Zepzelca's second-line indication.
- Jazz Pharmaceuticals (JAZZ) posted $15.4M Q2 2026 sales for Ziihera in biliary tract cancer. FDA granted Priority Review for HER2+ first‑line gastroesophageal sBLA; PDUFA date Aug 25, 2026. TradingView
- Jazz Pharmaceuticals (JAZZ) revenue grew driven by Xywav, Epidiolex and oncology launches; Xywav volumes and active patient count rose while high-sodium Xyrem volumes fell due to generics. TradingView
- Jazz Pharmaceuticals (JAZZ) ahead of earnings: mean EPS $6.18, revenue $1.12B; mean EPS rose ~3.7% in 3 months; consensus: 19 buy/strong buy, 1 hold; median 12‑mo target $275. Reuters
- Jazz Pharmaceuticals (JAZZ) will file an FDA labeling supplement in Q3 to remove Zepzelca's second‑line indication; the first‑line maintenance indication will stay unchanged. Reuters
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original sources.